Populate the sidearea with useful widgets. It’s simple to add images, categories, latest post, social media icon links, tag clouds, and more.
hello@youremail.com +1234567890
SFA Therapeutics
A New Paradigm for Treating Chronic Inflammatory Disease
A completely new approach to drug discovery and development.
A new platform in the treatment of chronic inflammatory disease.
– the use of endogenous biosythetics as drugs.
Previous
Next
Our Platform
Deriving drugs from bacterial metabolites found in man means no genotoxicity, faster clinical development and safer treatments.
Our pipeline includes treatments for Psoriasis, Liver Cancer (Hepatitis B, NASH and HCC), Ophthalmic Diseases, Cytokine Release Syndrome- a side effect in CAR-T, Prevention of Relapse/Recurrence in Leukemias, and other diseases.
Safer, Faster to Market and Lower R&D Cost
Our microbiome-derived drugs are derived from natural substances and enable a new platform to develop treatments which have the potential to treat over 85 chronic inflammatory diseases currently afflicting patients, providing safer treatments than current therapies.
Current Focus
SFA Therapeutics Currently has compounds in development in the current research areas
In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches. The Promise…
JENKINTOWN, Pa., May 2, 2024 /PRNewswire/ — SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory…
Ben Franklin Healthcare Investments Invests $1.3 Million in Four Companies Ben Franklin Healthcare Investments continues support of SFA Therapeutics with…